FOXP3 and cancer: The CD8+/FoxP3+ T cell ratio was commonly studied to predict the prognosis of patients and a meta-analysis indicated that a high CD8+/FoxP3+ T cell ratio was independently associated with improved survival based on the data from multiple cancer types [29].